Egg-derived adjuvanted influenza vaccine (Grippol Plus) - AbbVie

Drug Profile

Egg-derived adjuvanted influenza vaccine (Grippol Plus) - AbbVie

Alternative Names: Grippol Plus; Grippol Plus (egg-based adjuvanted seasonal vaccine)

Latest Information Update: 01 Feb 2013

Price : $50

At a glance

  • Originator Solvay Pharmaceuticals
  • Developer AbbVie
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott Laboratories
  • 06 Nov 2009 Launched for Influenza virus infections (prevention) in Russia (Parenteral); first global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top